SEC Recommends Bharat Biotech to Conduct Late-stage Trials, Submit Booster Protocol
2 years, 11 months ago

SEC Recommends Bharat Biotech to Conduct Late-stage Trials, Submit Booster Protocol

News 18  

The Subject Expert Committee of India’s drug authority has recommended Bharat Biotech to conduct late-stage trials for its intranasal vaccine BBV154. After discussions and deliberations for almost five hours on Tuesday, the expert panel has asked Bharat Biotech to add a Covishield arm in the booster trails and submit a protocol for the same. Bharat Biotech will submit a revised application tomorrow as per government sources. Bharat Biotech aims to conduct clinical trials on 5,000 healthy subjects: half or 2,500 individuals who have received Covishield and another 2,500 who have been administered Covaxin.

Sec Bharat Bharat Biotech  vaccine  recommends  sec  conduct  covishield  bharat  latestage  protocol  booster  expert  trials  biotech  intranasal  submit  expected

History of this topic

The right way to counter a poor Covaxin safety study
4 months, 3 weeks ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
7 months, 3 weeks ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

Over 7,000 Doses of Bharat Biotech's Intranasal Jab Ready for Market Rollout as Apex Lab Clears Batch 1
1 year, 10 months ago

Over 7,000 Doses of Bharat Biotech's Intranasal Jab Ready for Market Rollout as Apex Lab Clears Batch 1

News 18  

Over 7,000 doses of the world’s first intranasal Covid-19 vaccine, Bharat Biotech’s iNCOVACC, have been checked and released by the country’s apex vaccine testing laboratory, News18.com has learnt. BBV154, a novel adenovirus vectored intranasal vaccine for Covid-19, was sent to CDL in the first week of January in around six batches containing 15,000 doses. In polio, the dropper drops the …

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine
1 year, 10 months ago

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine

Hindustan Times  

Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday. The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's approval in November for restricted emergency use among adults as a heterologous booster dose. According to a statement issued …

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC
1 year, 10 months ago

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh collectively launched 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday in the national capital. Who all were present: On the occasion of the launch, the Union Minister of State Science & Technology; Minister of State Earth Sciences; MoS PMO, Personnel, Public …

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26
1 year, 11 months ago

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26

Hindustan Times  

Bhopal: Bharat Biotech’s nasal Covid-19 vaccine iNCOVACC is expected to be launched on January 26, executive chairman Krishna Ella said at an event on Saturday. “Our nasal vaccine will be officially launched on January 26 on Republic Day,” Ella told students at the Maulana Azad National Institute of Technology in Bhopal, where the India International Science Festival, 2022, is being …

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses
1 year, 11 months ago

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses

News 18  

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of Covid-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Bharat Biotech’s intranasal covid vaccine priced at ₹325 for govt hospitals
1 year, 11 months ago

Bharat Biotech’s intranasal covid vaccine priced at ₹325 for govt hospitals

Live Mint  

NEW DELHI: Bharat Biotech’s intranasal covid-19 vaccine--iNCOVACC --will be available for ₹325 per dose at government hospitals, and for ₹800 in private settings, the pharma major said on Tuesday. According to the company, iNCOVACC is the world’s first intranasal vaccine for covid-19 to have received approval for a primary two-dose schedule, and as a heterologous booster dose. Clinical trials were …

90L in city yet to get booster shot, but BMC has only 6K Covaxin doses
2 years ago

90L in city yet to get booster shot, but BMC has only 6K Covaxin doses

Hindustan Times  

Even as the country is bracing up for a possible surge in Covid-19 cases, the Brihanmumbai Municipal Corporation has only 6,000 Covaxin doses left while there have been no stocks of Covishield or Corbevax for the last few months. BMC’s executive health officer Dr Mangala Gomare said only 16% of the eligible population have received the booster dose and around …

Your Best Shot at Fighting Covid: 28% Have Already Taken Booster Dose, Finds Survey
2 years ago

Your Best Shot at Fighting Covid: 28% Have Already Taken Booster Dose, Finds Survey

News 18  

Amid government’s reminders for vaccine boosters in the wake of the Covid uptick in China, 28% of those surveyed by Localcircles said that they “have already taken the booster dose". However, 53% said that they “have not taken the booster dose and do not have any plans of taking it either". After the Centre’s meeting on Wednesday, Niti Aayog’s VK …

Bharat Biotech’s nasal vaccine to be available as booster dose
2 years ago

Bharat Biotech’s nasal vaccine to be available as booster dose

The Hindu  

With the threat of COVID-19 resurfacing and India ramping up preventive health surveillance measures, Health Minister Mansukh Mandaviya said on Friday that a vaccine, which could be administered as nasal drops, would henceforth be available for public use. “We have made available a nasal vaccine, developed by Bharat Biotech, that can be used as a precaution dose. A spokesperson for …

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN
2 years ago

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN

Firstpost  

The needle-free vaccine will be available at private centres. It will be introduced on the Co-WIN platform on Friday evening New Delhi: Bharat Biotech’s intranasal COVID-19 vaccine has been approved by the Ministry of Health and Family Welfare for inclusion in the vaccination programme as a booster dose for those above 18 years of age, official sources said on Thursday. …

Bharat Biotech misstated Covaxin trial data
2 years ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

50 million doses of Covaxin set to expire early 2023 due to poor offtake
2 years, 1 month ago

50 million doses of Covaxin set to expire early 2023 due to poor offtake

The Hindu  

Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said. Due to lack of product demand, production stoppage of Covaxin - a two dose jab, was initiated by Bharat Biotech earlier this year, though the vaccine maker …

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take
2 years, 1 month ago

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take

India TV News  

Highlights Covaxin lying with the firm are set to expire early next year There are no takers owing to poor demand, said company sources India reported 1,082 fresh COVID-19 cases on Saturday Covaxin news: Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers …

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences
2 years, 3 months ago

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences

News 18  

India will soon roll out mRNA shots and intranasal vaccines, which will be available on CoWIN, and can be used as boosters against Covid-19. India’s first mRNA shot is only the third mRNA vaccine to be approved for Covid-19 in the world after Pfizer and Moderna. But mortality will be reduced.” Sharing a study of the intranasal vaccines under clinical …

Bharat Biotech completes clinical development for phase III trials, booster doses for BBV154 intranasal COVID vaccine
2 years, 4 months ago

Bharat Biotech completes clinical development for phase III trials, booster doses for BBV154 intranasal COVID vaccine

Firstpost  

BBV154 has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that helps mass immunisation protect from emerging concern variants Hyderabad, Telangana: Bharat Biotech International on Monday said that BBV154 has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials. Product development related to preclinical safety evaluation, large-scale manufacturing scale-up, formulation, …

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech
2 years, 4 months ago

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech

Deccan Chronicle  

HYDERABAD: Bharat Biotech International Limited on Monday said its COVID-19 intranasal vaccine has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase III. Product development related to pre-clinical safety evaluation, large-scale manufacturing scale-up, formulation, and delivery device development, including human clinical trials, was conducted by Bharat Biotech. Suchitra K Ella, Joint Managing Director, Bharat Biotech, …

Corbevax as Covid booster for adults from August 12. Check details
2 years, 4 months ago

Corbevax as Covid booster for adults from August 12. Check details

India Today  

In a boost to India’s fight against coronavirus, the government gave nod to Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India's arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

India TV News  

Highlights Biological E's Corbevax has been approved as a booster or precaution dose. Covid vaccination: Biological E's Corbevax has been approved as a booster or precaution dose for those above the age of 18, and those who are fully vaccinated with either Covishield or Covaxin. "Corbevax will be considered as a precaution dose after completion of six months or 26 …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 4 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 4 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine this month
2 years, 4 months ago

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine this month

The Hindu  

Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of the company, Krishna Ella said. Clinical trials of nasal vaccine complete Mr. Ella said the firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no instance …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 5 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

COVID-19: Nasal vaccine's phase 3 trial completed, informs Bharat Biotech chief
2 years, 6 months ago

COVID-19: Nasal vaccine's phase 3 trial completed, informs Bharat Biotech chief

Firstpost  

Dr Krishna Ella said that the company will submit its data with Drugs Controller General of India next month and If everything is okay, it will be the world’s first clinically proven nasal COVID-19 vaccine Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday said that the clinical phase III trials of the COVID-19 nasal vaccine have …

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech
2 years, 6 months ago

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

The Hindu  

Bharat Biotech International Limited, on Friday, announced that COVID-vaccine Covaxin has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The company in its press release said that Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in 2-18 years …

NTAGI to Review Covaxin, Corbevax Data for 6-12 Yrs Thursday, Discuss Reducing Booster Dose Gap
2 years, 6 months ago

NTAGI to Review Covaxin, Corbevax Data for 6-12 Yrs Thursday, Discuss Reducing Booster Dose Gap

News 18  

Government advisory panel NTAGI will meet on Thursday to review data on Covaxin and Corbevax vaccines for the 6-12 age group and also deliberate on reducing the gap between the second and precaution doses from the current nine to six months. The agenda for the NTAGI's Standing Technical Sub-Committee meeting includes a discussion on a study by the CMC Vellore …

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin
2 years, 6 months ago

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin

The Hindu  

Hyderabad-based Biological E. Limited ’s COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination of Covaxin or Covishield vaccines for restricted use in emergency situations. ‘’Recently, BE furnished its clinical trials data to the DCGI, …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 6 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

Biological E seeks EUA of Corbevax as booster for Covishield, Covaxin recipients
2 years, 7 months ago

Biological E seeks EUA of Corbevax as booster for Covishield, Covaxin recipients

Live Mint  

Hyderabad-based Biological E has submitted an application to India's drug regulator, seeking emergency use authorisation for its Covid-19 vaccine Corbevax as a booster dose for adults who have been given two doses of either Covishield or Covaxin, reported news agency PTI, quoting sources. “We are now submitting the marketing authorization application for grant of permission Corbevax for restricted use in …

India Likely to Reduce Gap Between 2nd Covid Vaccine Shot, Booster Dose for Those Flying Abroad
2 years, 7 months ago

India Likely to Reduce Gap Between 2nd Covid Vaccine Shot, Booster Dose for Those Flying Abroad

News 18  

India may reduce the gap between the second Covid-19 vaccine shot and the precautionary third dose from nine to six months for citizens who are scheduled to travel abroad, especially to countries that have made it compulsory for travelers to produce their booster certificates. According to the advisory issued by the Union Ministry of Health and Family Welfare, the gap …

No Haste In Granting Emergency Use Authorization To Covaxin & Covishield: Supreme Court
2 years, 7 months ago

No Haste In Granting Emergency Use Authorization To Covaxin & Covishield: Supreme Court

Live Law  

In its judgment holding that the policy of the Union Government on COVID-19 vaccination policy is reasonable, the Supreme Court rejected the contention that restricted emergency use approvals had been granted to COVISHIELD and COVAXIN in haste, without thorough review of the relevant data.The court observed that the challenge to the procedures adopted by the expertbodies while granting. "However, it …

Centre’s decision on mix-and-match boosters likely in two weeks: Official
2 years, 8 months ago

Centre’s decision on mix-and-match boosters likely in two weeks: Official

Hindustan Times  

The government may be able to decide in two weeks whether to mix and match the booster doses of approved Covid-19 vaccines based on India-specific trial data being prepared by the Christian Medical College in Vellore, according to people familiar with the development. CMC Vellore, which was permitted to conduct homologous as well as heterologous booster dose trial by the …

Weighing the choices: on precautionary vaccine doses
2 years, 8 months ago

Weighing the choices: on precautionary vaccine doses

The Hindu  

As India sees a steady slump in its daily coronavirus count, the Centre has announced opening up the third, or ‘precautionary doses’, to everyone over 18 years. A major aspect of vaccines is the risk of adverse events following vaccination, and previous experience has suggested that certain vaccines may induce a higher risk of blood clots in younger populations. With …

Serum Institute to Give Free Covishield Vials to Private Vaccination Centres to Compensate for Price Difference
2 years, 8 months ago

Serum Institute to Give Free Covishield Vials to Private Vaccination Centres to Compensate for Price Difference

News 18  

A day after slashing the price of the precaution dose of Covishield to Rs 225 per shot for private hospitals, the Serum Institute of India told the Centre on Sunday that it will compensate for the price difference for the unexpired stocks lying with private centres in the form of free vials of fresh stocks, official sources said. Vaccine majors …

WHO pauses Covaxin supply via UN bodies
2 years, 8 months ago

WHO pauses Covaxin supply via UN bodies

The Hindu  

Bharat Biotech to upgrade facility The World Health Organisation on Saturday suspended supply of Bharat Biotech’s COVID vaccine, Covaxin, to allow the manufacturer to upgrade facilities and address deficiencies found during an inspection last month. ‘Will meet standards’ In a statement issued on April 1, Bharat Biotech said it was fully committed to implementing facility improvements and upgrades to ensure …

Why India's vaccine advisory body recommends reducing second-dose gap for Covishield
2 years, 9 months ago

Why India's vaccine advisory body recommends reducing second-dose gap for Covishield

Firstpost  

The National Technical Advisory Group on Immunisation has recommended that the gap between the first and second dose of Covishield should be reduced to eight to 16 weeks, from the current gap of 12 to 16 The National Technical Advisory Group on Immunisation has recommended that the gap between the first and second dose of Covishield should be reduced to …

2nd Covishield Dose Can Now Be Taken Between 8-16 Weeks After 1st Dose, No Word on Covaxin Yet
2 years, 9 months ago

2nd Covishield Dose Can Now Be Taken Between 8-16 Weeks After 1st Dose, No Word on Covaxin Yet

News 18  

The National Technical Advisory Group on Immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, officials said on Sunday. Under the National Covid-19 Vaccination Strategy, the second dose of Covishield is to be given between 12-16 weeks after the first dose. An official source said the latest recommendation of …

Covishield as Booster After 2 Doses of Covaxin Increases Antibodies by 6 Times: Study
2 years, 9 months ago

Covishield as Booster After 2 Doses of Covaxin Increases Antibodies by 6 Times: Study

News 18  

A recent study has found that Covishield is more effective when administered as a booster after two doses of Covaxin as antibodies zoom six-fold, however, the case is not the same when the vaccines are reversed. The study, submitted by Christian Medical College, Vellore, to the Drugs Controller General of India on Wednesday, is the first preliminary scientific evidence from …

Decision on mixing and matching of booster dose of Covid vaccines will be based on science: Govt
2 years, 9 months ago

Decision on mixing and matching of booster dose of Covid vaccines will be based on science: Govt

India Today  

The government on Thursday said that any decision on the mixing and matching of booster dose of COVID-19 vaccines will be taken based on science. Addressing a press conference here, NITI Aayog Member V K Paul said studies are going on regarding the mixing and matching of booster doses of Covid-19 vaccines and they are being "constantly reviewed". READ | …

US to evaluate Covaxin as COVID-19 vaccine candidate, announces Bharat Biotech
2 years, 10 months ago

US to evaluate Covaxin as COVID-19 vaccine candidate, announces Bharat Biotech

Firstpost  

The FDA has lifted its clinical hold on Bharat Biotech’s Investigational New Drug application to evaluate the COVID-19 vaccine candidate, BBV152, known as Covaxin outside the United States Hyderabad: Hyderabad-based Bharat Biotech on Saturday said its COVID-19 vaccine Covaxin will be evaluated as a vaccine candidate for the disease in the United States. “Ocugen, Inc announced that the US Food …

Bharat Biotech's intranasal COVID booster dose gets DGCI nod for phase 3 trials
2 years, 10 months ago

Bharat Biotech's intranasal COVID booster dose gets DGCI nod for phase 3 trials

Firstpost  

An intranasal vaccine would not only be simple to administer but also reduce the use of needles, the Covaxin-maker said. ‘BBV154’ is a replication-deficient adenovirus SARS-CoV-2 vectored vaccine New Delhi/Hyderabad: India’s drug regulator has given permission to Bharat Biotech to conduct phase-3 clinical trial for its intranasal Covid vaccine as booster dose on participants who have been previously inoculated with …

Bharat Biotech gets approval for intranasal Covid-19 booster dose trials
2 years, 10 months ago

Bharat Biotech gets approval for intranasal Covid-19 booster dose trials

India TV News  

Highlights Intranasal vaccine will be administered to those who have already taken their two-dose vaccine The interval between the second dose of Covid vaccine and booster dose will be six months According to Bharat Biotech, its nasal vaccine stimulates immune responses at the site of infection The Drugs Controller General of India has granted permission to Hyderabad-based biotechnology firm Bharat …

Panel pitches full market nod for Covaxin, Covishield
2 years, 11 months ago

Panel pitches full market nod for Covaxin, Covishield

Hindustan Times  

The subject expert panel of the national drugs regulator on Wednesday recommended full market authorisation for both Covaxin and Covishield under certain conditions, according to people familiar with the developments. Serum Institute of India and Bharat Biotech International Ltd, manufacturers of Covishield and Covaxin respectively, separately applied to the central drugs standard control organisation to seek full market authorisation stating …

SEC recommends Covaxin, Covishield for full market authorisation: Report
2 years, 11 months ago

SEC recommends Covaxin, Covishield for full market authorisation: Report

Hindustan Times  

The subject expert committee of the Central Drugs Standard Control Organisation on Wednesday recommended regular market approval for Covaxin and Covishield, the two most widely used jabs in the national vaccination drive against Covid-19, news agency PTI has reported, citing official sources. The development comes just days after the SEC, on January 14, sought more data from the two manufacturers--Hyderabad-based …

After SII's Covishield, Bharat Biotech Seeks Full Market Approval for Covaxin; SEC to Review Both Today
2 years, 11 months ago

After SII's Covishield, Bharat Biotech Seeks Full Market Approval for Covaxin; SEC to Review Both Today

News 18  

Bharat Biotech has sought full market approval for its Covid vaccine Covaxin from the country’s drug regulator, CNN-News18 has learnt from government sources. For full market authorisation, the regulator would need to evaluate more data about the vaccines collected over a longer period of time. Bharat Biotech’s Covaxin has also been exported to several counties through India’s Vaccine Maitri programme …

Covaxin booster shot neutralises Omicron, says Bharat Biotech
2 years, 11 months ago

Covaxin booster shot neutralises Omicron, says Bharat Biotech

Hindustan Times  

India's vaccine-maker Bharat Biotech on Wednesday said that a booster dose of its Covid-19 vaccine ‘Covaxin’ neutralises both the Omicron and Delta variants of the coronavirus. The study, "The neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant," Reuters quoted Bharat Biotech as saying in a statement. Citing the …

Holds promise: ICMR on trial results of third dose of Covaxin
2 years, 11 months ago

Holds promise: ICMR on trial results of third dose of Covaxin

Hindustan Times  

A day after Bharat Biotech released the trial results of the safety and immunogenicity of its Covid-19 vaccine ‘Covaxin’ as a booster shot, the Indian Council of Medical Research on Sunday affirmed the findings. Prime Minister Narendra Modi, in a televised address on December 25, 2021, announced precaution doses for healthcare and frontline workers from January 10 and Covid-19 jabs …

Discover Related